CA-VISA-INC.
6.12.2018 14:02:22 CET | Business Wire | Press release
Visa (NYSE:V), the Official Payment Services Partner of FIFA, has announced partnerships with the Union of European Football Associations’ (UEFA) Women’s Football Competitions and the Confederation of African Football (CAF) Total Africa Cup of Nations tournament to evolve its sponsorship portfolio and connect with fans around the world. Leveraging its sponsorship expertise and success at the 2018 FIFA World Cup Russia™, Visa will implement its innovative payment technology at the tournament venues and deliver exclusive experiences for cardholders and clients. By tapping into the strength of the Visa brand and its influential role for fans in football, Visa will help to further elevate women’s football and these regional tournaments.
“Visa has strategically positioned itself at the center of football and these events will further exemplify the unique experiences only Visa can provide to fans across the globe,” said Chris Curtin, chief brand and innovation marketing officer, Visa Inc. “These tournaments allow us distinctive opportunities to showcase Visa’s payment innovation, strengthen partnerships and highlight our evolved offerings to clients and fans.”
Expanding Global Football Portfolio
Visa is partnering with the UEFA Women’s Football Competitions through 2025 to continue its efforts to inspire and empower women, as women’s football continues to grow at all levels. Through its partnership, Visa will collaborate with UEFA for the 2021 Women’s European Championships in the United Kingdom and the annual Women’s Champions League beginning in 2019. Complementing the national team tournament with the world’s finest club competition allows Visa to be at the center of women’s football and strengthens its efforts around diversity, acceptance, and inclusion leading up to the FIFA Women's World Cup France 2019™.
Visa also announced its partnership with CAF as a sponsor of the Total Africa Cup of Nations (AFCON) tournament in 2019 and 2021. The deal will make Visa the exclusive payment services provider at all venues and the official partner of the player escort program. With CAF, Visa will be able to capitalize on football’s popularity throughout the continent, tap into high-growth markets and continue to deliver exclusive benefits to its local communities, clients, partners and fans as they come together to support the best of African football.
Driving Innovation around the Fan Experience
Visa, a FIFA partner since 2007, continues to drive toward new payment innovation that provides fans with faster and enhanced experiences at checkout. Whether it be remote and mobile ticket purchasing, contactless payment technology at transit locations, in-seat ordering or new ways to pay for retail, Visa will utilize its transit, retail and commerce expertise to deliver innovative payments that reimagine the fan experience.
These tournaments present an opportunity for the brand to build upon its success of 2018 FIFA World Cup Russia™. Visa brought contactless payment technology to 12 tournament stadiums and curated unforgettable experiences for more than 250 clients and 3,000 consumers who traveled from over a hundred different countries. In 103 markets around the world, Visa partnered with more than 500 issuers and 40 merchants in 24 languages on a variety of FIFA-related activities, whether to run custom marketing programs, host in-market viewing parties or utilize Visa’s exclusive marketing campaign assets to drive mutual business priorities.
FIFA Women's World Cup France 2019™ Ticket Presale for Visa Cardholders
Following the FIFA Women's World Cup France 2019™ Draw on December 8, Visa will offer an exclusive opportunity for cardholders to be the first fans to purchase individual match tickets for the tournament. The exclusive presale phase will take place from December 10 through December 23 and tickets for all matches will be available. FIFA recently announced that 150,000 FIFA Women's World Cup France 2019™ tickets have been sold since package sales opened in September.
About Visa Inc.
Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of connected commerce on any device, and a driving force behind the dream of a cashless future for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa , https://usa.visa.com/visa-everywhere/blog.html and @VisaNews .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181206005237/en/
Contact:
Visa Inc. Sheerin Salimi shesalim@visa.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom